Centre François Baclesse
Caen, France
54 recruiting
Showing 1–20 of 75 trials
Recruiting
Phase 3
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Squamous Cell Carcinoma of Head and Neck
UNICANCER102 enrolled26 locationsNCT04747054
Recruiting
Phase 2
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Triple-Negative Breast Cancer
UNICANCER354 enrolled44 locationsNCT06078384
Recruiting
Phase 3
Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers
Radiotherapy, AdjuvantOral Cavity CarcinomaFlap+1 more
Centre Francois Baclesse348 enrolled30 locationsNCT06798922
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
BioNTech SE480 enrolled171 locationsNCT06340568
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled318 locationsNCT07063745
Recruiting
Phase 4
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Metastatic Renal Cell CarcinomaLocally AdvancedRenal Cell Carcinoma (Kidney Cancer)
Centre Francois Baclesse83 enrolled19 locationsNCT07028125
Recruiting
Not Applicable
Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour
Intestinal Neuroendocrine Tumor
Institut Claudius Regaud150 enrolled10 locationsNCT06876532
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled286 locationsNCT07218380
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled211 locationsNCT06982521
Recruiting
Phase 2
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Malignant Solid Tumor
Centre Leon Berard455 enrolled13 locationsNCT04116541
Recruiting
Phase 3
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled37 locationsNCT05581121
Recruiting
Phase 2
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NSCLC Stage IVNSCLC Stage III
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 1Phase 2
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NSCLC
Ellipses Pharma265 enrolled52 locationsNCT05443126
Recruiting
Phase 3
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Colorectal, Cancer
Canadian Cancer Trials Group834 enrolled55 locationsNCT07152821
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled93 locationsNCT06162221
Recruiting
Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
Acrivon Therapeutics350 enrolled91 locationsNCT05548296
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Neuroendocrine TumorsProgressive DiseaseIntestinal Well Differentiated Endocrine Tumor
Institut du Cancer de Montpellier - Val d'Aurelle146 enrolled28 locationsNCT04954820
Recruiting
Phase 2Phase 3
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Ovarian CarcinosarcomaEndometrial Carcinosarcoma
ARCAGY/ GINECO GROUP138 enrolled36 locationsNCT03651206